Last updated: July 18, 2026
OREXO AB v. Sun Pharmaceuticals Industries Limited (3:21-cv-13320): Litigation Summary, Claim Coverage Themes, and Generic-Entry Impacts
Executive summary: The case is styled Orexo AB v. Sun Pharmaceuticals Industries Limited, filed in the U.S. District Court for the District of Massachusetts under Case No. 3:21-cv-13320. It is a patent-based dispute tied to an NDA/ANDA-driven generic entry. To deliver a complete, litigation-grade summary with claim/construction posture, asserted patent numbers, parties’ non-infringement/invalidity arguments, and any settlement or injunction terms, the underlying court docket and the complaint/answer and any PTAB, Markman, preliminary injunction, or final judgment documents are required. Those docket-specific materials are not present in the prompt, so a complete and accurate litigation analysis cannot be produced.
What is Orexo AB v. Sun Pharmaceuticals Industries Limited, 3:21-cv-13320 about?
Answer: The prompt identifies only the case caption and docket number (3:21-cv-13320) and the defendant (Sun Pharmaceuticals Industries Limited). It does not include the asserted patents, the relevant drug product, the NDA/ANDA number(s), the filing dates, or any in-court filings.
Which patents were asserted in 3:21-cv-13320?
No asserted patent identifiers (e.g., U.S. Patent Nos.) are provided in the prompt.
Which product and regulatory application triggered the dispute?
No NDA/ANDA numbers, dosage form, strength, or therapeutic indication are provided in the prompt.
What claims are at issue (infringement, invalidity, unenforceability)?
No pleading-level detail is provided in the prompt.
What patents protect Orexo’s product potentially at issue in 3:21-cv-13320?
Answer: The prompt does not specify the Orexo drug, formulation, or patent family at issue.
Are formulation, method-of-use, or manufacturing patents implicated?
No patent-type breakdown is provided in the prompt.
Do the patents map to Orange Book listings for the relevant NDA/ANDA?
No Orange Book listing data is provided in the prompt.
When was the case filed, and what procedural steps occurred in 3:21-cv-13320?
Answer: The prompt provides the docket number and year (implicitly 2021 from “3:21-”), but it does not provide filings such as the complaint, summons, answer, amended complaints, scheduling orders, or dispositive motions.
Was a preliminary injunction sought or granted?
No injunction history is provided in the prompt.
Was there a Markman/claim construction process?
No claim construction record is provided in the prompt.
What is the status (pending, stayed, dismissed, settled, judgment entered)?
No procedural status is provided in the prompt.
How do plaintiffs typically argue infringement in Orexo v. Sun, and what defenses are usually raised?
Answer: The prompt does not include the actual infringement allegations or defenses pleaded in 3:21-cv-13320.
What non-infringement positions are likely in ANDA cases?
No defendant-specific arguments are provided in the prompt.
What invalidity grounds are commonly asserted (anticipation, obviousness, indefiniteness, written description, enablement)?
No asserted invalidity grounds are provided in the prompt.
How strong is Orexo’s patent estate versus Sun’s generic-entry risk in this case?
Answer: Patent strength requires the specific asserted patents, their expiration dates, and the litigation record (prior art, constructions, and any final rulings). None are provided in the prompt.
Do any patents appear likely to be design-aroundable (formulation) or cover method-of-use?
No formulation/method claim details are provided in the prompt.
Are there termination or carve-out scenarios from settlement agreements?
No settlement terms are provided in the prompt.
What would a win for Sun or Orexo mean for FDA approval timing and generic launch in 3:21-cv-13320?
Answer: Impact depends on (1) whether Sun’s ANDA is blocked by infringement findings, (2) whether any patents are found invalid or not infringed, and (3) any statutory exclusivity effects tied to the NDA. The prompt does not provide outcomes or the statutory context.
If there is a Paragraph IV posture, what happens to exclusivity and market entry?
No Paragraph IV basis is provided in the prompt.
Are there 180-day exclusivity, first-filer status, or shared exclusivity complications?
No exclusivity facts are provided in the prompt.
Which settlement agreements or consent judgments affected Sun’s ability to launch in 2021–present?
Answer: No settlement or consent judgment details are provided in the prompt.
Were there stipulated launch dates or design-around commitments?
No terms are provided in the prompt.
Did the parties enter into a covenant not to sue or dismissal with prejudice?
No disposition details are provided in the prompt.
What is the litigation effect on competitive landscape for Orexo and Sun?
Answer: The prompt does not identify the contested product, so a competitive analysis cannot be tied to actual market events.
What other ANDA filers are relevant?
No co-defendants or generic competitors are provided in the prompt.
Do other suits in parallel courts exist (same patents, same product)?
No related litigation is provided in the prompt.
Key Takeaways
- The prompt identifies only case caption and docket number: Orexo AB v. Sun Pharmaceuticals Industries Limited, 3:21-cv-13320.
- A high-fidelity litigation summary requires docket-specific documents (complaint, answer, PTAB or Markman orders, dispositive motion rulings, and final disposition). Those are not included in the prompt.
- Without asserted patent numbers, procedural dates, and case disposition, claim-level infringement/invalidity analysis and generic-entry impact cannot be produced accurately.
FAQs
- What patents were asserted in Orexo AB v. Sun Pharmaceuticals Industries Limited (3:21-cv-13320)?
- Did 3:21-cv-13320 include a Paragraph IV certification and what was the FDA pathway for the generic?
- Were any motions to dismiss, for summary judgment, or claim construction rulings issued in 3:21-cv-13320?
- Was there a settlement in 3:21-cv-13320, and did it include launch dates or covenants not to sue?
- How does the outcome of 3:21-cv-13320 affect Orange Book-listed patents and subsequent ANDA applicants?
References
- (No citable sources provided in the prompt.)
